GLP-3 (retatrutide) Research
Triple GLP-1 / GIP / Glucagon Receptor Agonist
metabolic signaling research
Weight and Wellness
Educational information only. Investigational uses may lack FDA approval. Not medical advice or a treatment plan.
Retatrutide is an investigational triagonist peptide that acts simultaneously at GLP-1, GIP, and glucagon receptors. Unlike dual agonists such as tirzepatide, its additional activity at the glucagon receptor is thought to contribute to energy expenditure signaling. It is currently being studied in clinical trials for its role in metabolic signaling pathways related to energy regulation, body composition, and glycemic control.
Research areas
GLP-1 Receptor Signaling
Research investigates retatrutide's agonism at glucagon-like peptide-1 receptors, exploring downstream effects on insulin secretion signaling, appetite-regulating neural pathways, and gastric motility research.
GIP Receptor Signaling
Studies examine its activity at glucose-dependent insulinotropic polypeptide (GIP) receptors, including incretin signaling, pancreatic beta-cell function research, and interaction with insulin sensitivity pathways.
Glucagon Receptor Signaling
Researchers study its glucagon receptor agonism and its potential role in energy expenditure signaling, hepatic glucose output modulation, and lipolysis-related pathway research — a mechanism that distinguishes it from GLP-1/GIP dual agonists.
Metabolic and Glycemic Signaling
Clinical research explores retatrutide's effects on blood glucose regulation pathways, insulin resistance signaling, and metabolic rate research in subjects with obesity or type 2 diabetes.
Body Composition Research
Phase 2 trial data are being analyzed for retatrutide's effects on fat mass reduction, lean mass preservation, and adipose tissue signaling pathways.
Cardiovascular Pathway Research
Ongoing studies investigate potential effects on cardiovascular risk-related signaling, including lipid metabolism pathways, blood pressure regulation research, and cardiometabolic biomarker investigations.
Investigational compound. Not FDA-approved. Phase 2 clinical trials have been completed; Phase 3 trials are ongoing. Not medical advice.
Have questions about GLP-3 (retatrutide)?
Request a free consultation to ask questions and learn more about this research area.
Request a free consultation